Cytokinetics (CYTK) Stock Forecast & Price Target

$43.63 -0.92 (-2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$43.92 +0.28 (+0.65%)

As of 07:26 PM Eastern

Cytokinetics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
2

Buy
16

Based on 18 Wall Street analysts who have issued ratings for Cytokinetics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 2 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for CYTK.

Consensus Price Target

$82.00
87.94% Upside

According to the 18 analysts' twelve-month price targets for Cytokinetics, the average price target is $82.00. The highest price target for CYTK is $120.00, while the lowest price target for CYTK is $60.00. The average price target represents a forecasted upside of 87.94% from the current price of $43.63.

Get the Latest News and Ratings for CYTK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cytokinetics and its competitors.

CYTK Analyst Ratings Over Time

Type	Current Forecast 3/26/24 to 3/26/25	1 Month Ago 2/25/24 to 2/24/25	3 Months Ago 12/27/23 to 12/26/24	1 Year Ago 3/27/23 to 3/26/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	15 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$82.00	$82.00	$84.07	$77.00
Forecasted Upside	87.94% Upside	70.34% Upside	73.19% Upside	8.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

CYTK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYTK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cytokinetics Stock vs. The Competition

Type	Cytokinetics	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	87.94% Upside	29,811.02% Upside	17.62% Upside
News Sentiment Rating	Positive News See Recent CYTK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/7/2025	Morgan Stanley 3 of 5 stars		Set Target		$67.00	+55.38%
2/28/2025	HC Wainwright 1 of 5 stars	Joseph Pantginis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+152.90%
2/7/2025	Evercore ISI 2 of 5 stars	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/7/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00 ➝ $78.00	+78.65%
2/7/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00	+86.27%
2/6/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Serge Belanger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00	+55.06%
1/22/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Condulis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00	+74.60%
12/18/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Timashev Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$80.00 ➝ $82.00	+66.87%
11/21/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$99.00 ➝ $103.00	+106.58%
10/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
Get the Latest News and Ratings for CYTK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.
9/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$65.00 ➝ $71.00	+27.26%
8/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Choi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.80%
6/4/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$122.00 ➝ $92.00	+89.81%
5/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $70.00	+45.20%
5/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$70.00 ➝ $60.00	+20.53%
5/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$100.00 ➝ $95.00	+92.19%
5/23/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $70.00	+42.80%
5/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$107.00 ➝ $106.00	+65.08%
1/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$61.00 ➝ $92.00	+8.49%
8/15/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/15/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%
8/15/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:20 PM ET.

CYTK Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Cytokinetics is $82.00, with a high forecast of $120.00 and a low forecast of $60.00.
: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
: According to analysts, Cytokinetics's stock has a predicted upside of 87.94% based on their 12-month stock forecasts.
: Over the previous 90 days, Cytokinetics's stock had 2 upgrades by analysts.
: Cytokinetics has been rated by research analysts at Citigroup, Evercore ISI, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, and Stifel Nicolaus in the past 90 days.
: Analysts like Cytokinetics more than other "medical" companies. The consensus rating score for Cytokinetics is 2.94 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CYTK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CYTK) was last updated on 3/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Stock Forecast & Price Target